Literature DB >> 25934693

miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.

A H Mirnezami1,2, N J Peake1, D Cellura1, K Pickard1, S Quaratino1, H Parker3, J C Strefford3, G J Thomas1, R Mitter4.   

Abstract

UNLABELLED: Transglutaminase-2 (TG2) is a critical cross-linking enzyme in the extracellular matrix (ECM) and tumor microenvironment (TME). Although its expression has been linked to colorectal cancer, its functional role in the processes that drive disease appears to be context dependent. There is now considerable evidence of a role for microRNAs (miRNA) in the development and progression of cancer, including metastasis. A cell model of metastatic colon adenocarcinoma was used to investigate the contribution of miRNAs to the differential expression of TG2, and functional effects on inflammatory and invasive behavior. The impact of TG2 in colorectal cancer was analyzed in human colorectal tumor specimens and by manipulations in SW480 and SW620 cells. Effects on invasive behavior were measured using Transwell invasion assays, and cytokine production was assessed by ELISA. TG2 was identified as a target for miR-19 by in silico analysis, which was confirmed experimentally. Functional effects were evaluated by overexpression of pre-miR-19a in SW480 cells. Expression of TG2 correlated inversely with invasive behavior, with knockdown in SW480 cells leading to enhanced invasion, and overexpression in SW620 cells the opposite. TG2 expression was observed in colorectal cancer primary tumors but lost in liver metastases. Finally, miR-19 overexpression and subsequent decreased TG2 expression was linked to chromosome-13 amplification events, leading to altered invasive behavior in colorectal cancer cells. IMPLICATIONS: Chromosome-13 amplification in advanced colorectal cancer contributes to invasion and metastasis by upregulating miR-19, which targets TG2. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25934693      PMCID: PMC4529484          DOI: 10.1158/1541-7786.MCR-14-0466

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  58 in total

1.  Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential.

Authors:  Erin L Baker; Jing Lu; Dihua Yu; Roger T Bonnecaze; Muhammad H Zaman
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

Review 2.  MicroRNAs: key players in carcinogenesis and novel therapeutic targets.

Authors:  A H F Mirnezami; K Pickard; L Zhang; J N Primrose; G Packham
Journal:  Eur J Surg Oncol       Date:  2008-07-21       Impact factor: 4.424

3.  Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases.

Authors:  Christoph Kahlert; Fee Klupp; Karsten Brand; Felix Lasitschka; Sven Diederichs; Johanna Kirchberg; Nuh Rahbari; Shamik Dutta; Ulrich Bork; Johannes Fritzmann; Christoph Reissfelder; Moritz Koch; Juergen Weitz
Journal:  Cancer Sci       Date:  2011-08-04       Impact factor: 6.716

Review 4.  Alterations of microRNAs contribute to colon carcinogenesis.

Authors:  Aaron J Schetter; Curtis C Harris
Journal:  Semin Oncol       Date:  2011-12       Impact factor: 4.929

5.  Expression of tissue transglutaminase in human bladder carcinoma.

Authors:  H Hager; P H Jensen; S Hamilton-Dutoit; M S Neilsen; P Birckbichler; J Gliemann
Journal:  J Pathol       Date:  1997-12       Impact factor: 7.996

6.  Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.

Authors:  Amit Verma; Sushovan Guha; Huamin Wang; Jansina Y Fok; Dimpy Koul; James Abbruzzese; Kapil Mehta
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer.

Authors:  Amit Verma; Sushovan Guha; Parmeswaran Diagaradjane; Ajaikumar B Kunnumakkara; Angela M Sanguino; Gabriel Lopez-Berestein; Anil K Sood; Bharat B Aggarwal; Sunil Krishnan; Juri G Gelovani; Kapil Mehta
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

9.  Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma.

Authors:  Yulin Sun; Wei Mi; Jianqiang Cai; Wantao Ying; Fang Liu; Haizhen Lu; Yuanyuan Qiao; Wei Jia; Xinyu Bi; Ning Lu; Shangmei Liu; Xiaohong Qian; Xiaohang Zhao
Journal:  J Proteome Res       Date:  2008-07-23       Impact factor: 4.466

10.  Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells.

Authors:  Thung-S Lai; Yusha Liu; Weidong Li; Charles S Greenberg
Journal:  FASEB J       Date:  2007-07-03       Impact factor: 5.191

View more
  35 in total

1.  Metabolic syndrome is a predictor of all site and liver-specific recurrence following primary resection of colorectal cancer: Prospective cohort study of 1006 patients.

Authors:  Rahul Bhome; Nadia Peppa; Shoura Karar; Declan McDonnell; Alex Mirnezami; Zaed Hamady
Journal:  Eur J Surg Oncol       Date:  2021-01-07       Impact factor: 4.424

2.  Targeted Quantitative Profiling of GTP-Binding Proteins in Cancer Cells Using Isotope-Coded GTP Probes.

Authors:  Rong Cai; Ming Huang; Yinsheng Wang
Journal:  Anal Chem       Date:  2018-11-28       Impact factor: 6.986

3.  TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.

Authors:  Han Zhang; Zheng Chen; Roberto N Miranda; L Jeffrey Medeiros; Nami McCarty
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

4.  Development of Novel Monoclonal Antibodies for Evaluation of Transmembrane Prostate Androgen-Induced Protein 1 (TMEPAI) Expression Patterns in Gastric Cancer.

Authors:  Mikhail S Karbyshev; Evgeniya S Grigoryeva; Viktor V Volkomorov; Elisabeth Kremmer; Alexander Huber; Irina V Mitrofanova; Evgeniya V Kaigorodova; Marina V Zavyalova; Julia G Kzhyshkowska; Nadezda V Cherdyntseva; Evgeny L Choynzonov
Journal:  Pathol Oncol Res       Date:  2017-06-05       Impact factor: 3.201

5.  miR-19a promotes colitis-associated colorectal cancer by regulating tumor necrosis factor alpha-induced protein 3-NF-κB feedback loops.

Authors:  T Wang; X Xu; Q Xu; J Ren; S Shen; C Fan; Y Hou
Journal:  Oncogene       Date:  2016-12-19       Impact factor: 9.867

6.  Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Chengbo Yu; Qing Cao; Ping Chen; Shigui Yang; Xianli Gong; Min Deng; Bing Ruan; Lanjuan Li
Journal:  Tumour Biol       Date:  2016-10-25

7.  MiR-19a suppresses ferroptosis of colorectal cancer cells by targeting IREB2.

Authors:  Hongwei Fan; Rong Ai; Suen Mu; Xuemin Niu; Zhengrong Guo; Lin Liu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

8.  Prognostic role of tissue transglutaminase 2 in colon carcinoma.

Authors:  María Jesús Fernández-Aceñero; Sofía Torres; Irene Garcia-Palmero; Cristina Díaz Del Arco; J Ignacio Casal
Journal:  Virchows Arch       Date:  2016-09-13       Impact factor: 4.064

Review 9.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

10.  Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53.

Authors:  Patrizia Malkomes; Ilaria Lunger; Elsie Oppermann; Khalil Abou-El-Ardat; Thomas Oellerich; Stefan Günther; Can Canbulat; Sabrina Bothur; Frank Schnütgen; Weijia Yu; Susanne Wingert; Nadine Haetscher; Claudia Catapano; Marina S Dietz; Mike Heilemann; Hans-Michael Kvasnicka; Katharina Holzer; Hubert Serve; Wolf Otto Bechstein; Michael A Rieger
Journal:  Oncogene       Date:  2021-06-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.